Guardant Health Reports $231.3 million in Latest Quarterly Results
Guardant Health reported quarterly results highlighted by Oncology revenue grew 25% to $231.3 million, according to its earnings release filed with an 8-K Thursday.
creening revenue grew 180% to $67.6 million. rma & Data revenue grew 8% to $59.0 million. ◦ Biopharma & Data revenue of $59.0 million, an increase of 8%.
Results detail
Further figures in the release included Reported total revenue of $361.0 million, an increase of 36%, driven by:; Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%; ◦ Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield tests, an increase of 246%.
The filing is an Item 2.02 results announcement furnished with Exhibit 99.1. Comparisons use the year-earlier period as presented by Guardant Health unless the release specifies another baseline. Where both GAAP and non-GAAP metrics appear, both are summarized when the extract includes them.
Segment mix, cash flow and any outlook language in the release are the usual secondary reads after the headline revenue and earnings figures.
Why it matters
For retail investors, the Guardant Health print is a check on whether growth, margins and cash generation are moving together. The figures above come from the company’s Exhibit 99.1 earnings materials; how they stack up against the prior-year run rate and any guide published with the release will shape the near-term debate.
By the numbers
- Oncology revenue grew 25% to $231.3 million
- creening revenue grew 180% to $67.6 million
- rma & Data revenue grew 8% to $59.0 million
- ◦ Biopharma & Data revenue of $59.0 million, an increase of 8%
- Reported total revenue of $361.0 million, an increase of 36%, driven by:
- Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%
Sources
- Guardant Health, Inc. Form 8-K with quarterly financial results, filed Nov. 5, 2026 (accession 0001576280-26-000043)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.